Symbol="ADAP"
AssetType="Common Stock"
Name="Adaptimmune Therapeutics Plc"
Description="Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to solid tumor patients in the United States and the United Kingdom. The company is headquartered in Abingdon, the United Kingdom."
CIK="1621227"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, GB"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="198610000"
EBITDA="-102003000"
PERatio="None"
PEGRatio="0.11"
BookValue="0.506"
DividendPerShare="0"
DividendYield="0"
EPS="-0.67"
RevenuePerShareTTM="0.436"
ProfitMargin="-1.604"
OperatingMarginTTM="-1.522"
ReturnOnAssetsTTM="-0.191"
ReturnOnEquityTTM="-0.924"
RevenueTTM="71174000"
GrossProfitTTM="-100578000"
DilutedEPSTTM="-0.67"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="12.31"
AnalystTargetPrice="5.58"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="11.77"
PriceToBookRatio="1.995"
EVToRevenue="2.784"
EVToEBITDA="-0.283"
Beta="2.222"
num_52WeekHigh="2.65"
num_52WeekLow="0.868"
num_50DayMovingAverage="0.998"
num_200DayMovingAverage="1.413"
SharesOutstanding="225054000"
DividendDate="2018-03-30"
ExDividendDate="None"
symbol="ADAP"
open="0.90"
high="0.92"
low="0.88"
price="0.88"
volume="381327.00"
latest_trading_day="2023-08-02"
previous_close="0.91"
change="-0.03"
change_percent="-3.0590%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="100"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="0"
Volume_recent_avg="857985"
Change_recent_avg="0.01"
Delta_recent_avg="0.08"
Variance_recent_avg="0.04"
Change_ratio_recent_avg="-0.53"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="0"
Aroon_momentum_negative="100"
image_negative_thumbnail_id_1="100"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0076.jpeg"
image_negative_thumbnail_id_2="120"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0056.jpeg"
image_neutral_thumbnail_id_1="557"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0042.jpeg"
image_neutral_thumbnail_id_2="530"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0069.jpeg"
image_positive_thumbnail_id_1="1000"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0162.jpeg"
image_positive_thumbnail_id_2="618"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0090.jpeg"
image_professor_thumbnail_id_1="1184"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
image_professor_thumbnail_id_2="1185"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0019.jpeg"
